● SK bioscience, receives award from MFDS (Minister of Food and Drug Safety) in Medical Korea 2018
- Achieving vaccine sovereignty due to self-developed vaccine including flu, zoster, varicella
- Awarded 4 consecutive years after the launch of ‘SKY Cell Flu’ in 2015SK bioscience won an award from the Minister of Food and Drug Safety in recognition of its contribution to vaccine business this year.
SK bioscience announced that it won the award from the Minister of Food and Drug Safety for its contributions to the domestic pharmaceutical and bio industry at the ＇2018 Medical Korea Award＇ ceremony held at the Grand Intercontinental Parnas Hotel, Seoul on the 21st.
MEDICAL KOREA won the 11th prize this year as an award ceremony to select top pharmaceutical companies, medical equipment companies, hospitals, medical clinics, etc., which led the development of the pharmaceutical and bio industries in that year. The event was sponsored by the Ministry of Health and Welfare and the Ministry of Food and Drug Safety.
SK bioscience gained recognition for raising the level of R&D technology of the domestic vaccine industry by producing self-developed vaccines that include the world＇s first tetravalent cell culture flu vaccine, ‘SKY CellfluQuadrivalent,’ ‘SKY Zoster,’ a zoster vaccine which raised the domestic self-sufficiency to 50%, and Korea’s second varicella vaccine ‘SKY Varicella.’
This is not the first time SK bioscience has been honored by a Medical Korea Award.
They never missed an award for 4 years in a row starting when ‘SKY Cell Flu’ was awarded the Grand Prize in the Medical Korea Awards vaccine category in 2015, before it was split off from parent company SK chemicals.
SKY Cell Flu Quadrivalent is a cell-culture flu vaccine that can prevent four types of influenza viruses once inoculated. Cell culture flu vaccine production technology is fast and efficient in production because it uses animal cells instead of a fertilized egg. In addition, since the production period is only one-half that of a fertilized egg and without using antibiotics or preservatives in the manufacturing process, it can cope more quickly with emergency situations resulting from unpredicted flu types.
Based on these strengths, SK bioscience began exporting its high-efficiency flu vaccine production technology of cell-cultivated style to global vaccine companies last February.
In addition, SK bioscience broke the monopoly structure of the herpes zoster vaccine market in Korea through the launch of the zoster vaccine ＇Sky Zoster,＇ and in September, it presented the vaccine ＇SKY Varicella.＇
SK bioscience CEO Ahn Jae-yong said, "It seems that the outstanding achievements of domestic and overseas vaccines have returned to meaningful awards." and “We will continue to be a Global Vaccine Technology Innovator, and a leader in changing the global market beyond Korea through continuous R & D investment."
# Description: SK bioscience CEO Ahn Jae-Yong (right) is awarded with an award from the Minister of Food and Drug Safety, Medical Korea.